Xu, Haifeng C. http://orcid.org/0000-0002-4674-4983
Wang, Ruifeng
Shinde, Prashant V.
Walotka, Lara
Huang, Anfei
Poschmann, Gereon http://orcid.org/0000-0003-2448-0611
Huang, Jun
Liu, Wei
Stühler, Kai
Schaal, Heiner http://orcid.org/0000-0002-1636-4365
Bergthaler, Andreas http://orcid.org/0000-0003-0597-1976
Pandyra, Aleksandra A.
Hardt, Cornelia
Lang, Karl S.
Lang, Philipp A. http://orcid.org/0000-0001-5341-0407
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (RTG 1949, SFB 974)
Article History
Received: 29 September 2020
Accepted: 12 March 2021
First Online: 29 April 2021
Competing interests
: The authors declare the following competing interests: H.C.X., R.W., A.H., C.H., K.S.L., and P.A.L. declare that they are involved in the development of LCMV for clinical application in oncology in cooperation with or as advisors to Abalos Therapeutics GmbH.